The global insurtech market is projected to grow from $14 billion in 2026 to $638 billion by 2035, at a CAGR of 41.45%. Growth is driven by AI, blockchain, cloud computing, and machine learning technologies, with collaborations between traditional insurers and startups accelerating innovation. North America leads the market, while Asia is expected to grow faster. Health insurance, managed services, and cloud computing segments dominate, with healthcare sector showing highest future growth potential.

Fiserv reported disappointing Q3 earnings, with revenue and earnings missing analyst expectations, leading to a 30% stock collapse and a comprehensive strategic restructuring including leadership changes and reduced financial guidance.

Chamath Palihapitiya launched a new SPAC called American Exceptionalism Acquisition Corp, but is advising retail investors to avoid it due to high risk and complex investment structure. He emphasized that 98.7% of the SPAC was allocated to institutional investors.

The global AI in healthcare market is projected to reach nearly $700 billion by 2034, growing at 38.5% annually. Companies are developing advanced AI diagnostic technologies targeting areas like diabetic retinopathy, cardiac screening, and chronic disease management, with increasing FDA approvals and commercial potential.

The healthcare AI market is projected to surge at a 30% compound annual growth rate through 2030, driven by increased investment across hospitals, insurers, and pharma. Companies like Avant Technologies, Amesite, Oracle, Clover Health, and Alphabet are making advancements in AI-powered healthcare solutions.

The healthcare AI market is projected to surge at a 30% compound annual growth rate through 2030, driven by new investments across hospitals, insurers, and pharma. Companies like Avant Technologies, Amesite, Oracle, Clover Health, and Alphabet are making advancements in AI-powered healthcare solutions.

Clover Health announced that Lee A. Shapiro will not stand for re-election to the Board of Directors, and Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee.

Hindenburg Research, a notable short-seller, has targeted several high-profile stocks with scathing reports, leading to significant stock price declines. The article examines the impact of Hindenburg's reports on Clover Health, DraftKings, and Block, and discusses the potential risks and biases associated with short-seller reports.

FRANKLIN, Tenn., June 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Clover Health Investments Corp (NASDAQ:CLOV) shares are trading higher in Thursday’s after-hours session following insider buying from the company’s co-founder. What Happened: After the market close on Thursday, Clover Health filed a Form 4 with the SEC showing that co-founder and executive chair Vivek Garipalli purchased 877,567 shares of Clover Health stock at an average price of $1.14 per share. The shares were bought on June 17 in multiple transactions at prices ranging from $1.08 to $1.17. ...Full story available on Benzinga.com

The Company previously communicated that CMS had calculated a rating of 3.0 Stars for its PPO plans, impacting payment year 2025. As a result of a recent rating recalculation, CMS has improved that rating to 3.5 Stars for 2025 payment year The Company previously communicated that CMS had calculated a rating of 3.0 Stars for its PPO plans, impacting payment year 2025. As a result of a recent rating recalculation, CMS has improved that rating to 3.5 Stars for 2025 payment year

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 28.57% and 9.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?